Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Recruiting now · Phase 2/Phase 3

Conditions studied: Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult

In brief

The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?

Key facts

Study ID

NCT05595447

Run by

Hospital Regional de Alta Especialidad del Bajio

People needed

20

Starts

2022-10-18

Expected to finish

2025-10-18

Last updated by the study team

2025-03-12

Who can join

Age: 15 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk.
• Age ≥ 18 years and ≤ 90 years.
• Adequate liver function, defined as:
• Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
• Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN
• Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN
• Adequate renal functions, defined as:
• Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \> 50ml/min.
• ECOG performance status ≤ 3
• Women of reproductive potential should have a serum pregnancy test or negative urine.
• Prior signature of the informed consent.

You may not qualify if…

• Voluntary withdrawal from the study.
• Develop grade 3 or 4 toxicity according to the INH scale.
• Loss of follow-up

Where it is running

• Hospital Regional Alta Especialidad Bajio — León, Guanajuato, Mexico (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.